Go Ad-Free
logoThe People's Perspective on Medicine

New Drug to Ease Pain of Endometriosis

The FDA has just approved elagolix (Orilissa) to ease moderate to severe pain from endometriosis. This should be a welcome relief for some women, but beware side effects and cost.

Endometriosis makes women miserable. In this condition, tissue that normally lines the uterus (endometrial tissue) escapes and proliferates elsewhere in the pelvic cavity. This problem affects as many as one woman out of every ten. Frequently, it leads to extremely painful and copious menstrual periods. Women with endometriosis may also suffer pain at other times, including during sexual activity. In addition, women with significant endometriosis may have trouble conceiving when they wish to have babies.

New Treatment for Endometriosis Pain:

The Food and Drug Administration just approved a new drug for treating moderate to severe endometriosis pain. Elagolix will be sold under the brand name ORILISSA. It works by blocking receptors for gonadotropin releasing hormone, or GnRh. This in turn lowers levels of the female hormones estradiol and progesterone.

According to studies published in the New England Journal of Medicine, elagolix relieved pelvic pain better than placebo. The researchers noted, however, that lower levels of estrogen were associated with reduced bone mineral density, more hot flashes, and increases in LDL cholesterol. The official prescribing information also warns about depression, mood changes and headaches as well as liver enzyme elevations.

Because of concern about side effects, especially lower bone mineral density, women will be able to take the lower dose (150 mg once a day) for up to two years, not longer. They will be limited to six months’ use of the higher dose (200 mg twice a day). Otherwise, this treatment for endometriosis pain could result in painful bone fractures from drug-induced osteoporosis later on.

Side Effect for the Wallet:

The oral medication is expected to cost as much as $10,000 per year. Because the drug is not a cure, women will need to take it indefinitely. Orilissa approval has bolstered the stock price of AbbVie, its manufacturer, but it is not clear how many insurance plans will pay for this medication.

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
5- 7 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies..
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.